ELUTIA INC. (ELUT) Form 10-Q — Aug 14, 2026
Elutia reported Q2 2026 net sales of $2.4 million, down 11.6% year over year, with a quarterly net loss of $7.6 million and a first-half net loss of $15.1 million as R&D spending on its NXT-41 programs more than doubled. Cash fell to $19.9 million from $36.4 million at year-end after $16.3 million of operating cash burn, and on August 11, 2026 the company closed a $15 million senior secured term loan with Avenue funds bearing interest of at least 12.25%, with $10 million funded and warrants on 1.4 million shares at up to $0.86 issued to the lenders.
Key figures
- Revenue
- 2427000
- Revenue Yoy
- -11.6%
- Total Assets
- 43649000
- Cash Position
- 19896000
- Shares Outstanding
- 44289230
- Loan maturity
- 2030-03-01
- H1 2026 revenue
- 5541000
- Q2 2025 revenue
- 2747000
- Cash dec 31 2025
- 36350000
- Loan interest rate
- greater of 12.25% or WSJ Prime + 5.50%
- Accumulated deficit
- 191328000
- Stockholders equity
- 15746000
- Medtronic settlement
- $1.78 million in installments, or $1.513 million if paid in full by June 17, 2027
- Q2 2026 gross margin
- 59.6%
- Lender warrants shares
- 1395348
- New term loan facility
- up to $15 million ($10M funded Aug 11, 2026; $5M delayed draw)
- Vbm litigation liability
- 3000000
- Cied divestiture proceeds
- up to $88.0 million ($80.4M received; $8.0M in escrow)
- Contingent legal liability
- 5619000
- Operating cash use h1 2026
- 16300000
- Fibercel litigation liability
- 1100000
- Simpliderm sale consideration
- up to $11 million ($8M cash base, $2M milestones, $1M earn-out)
- Fibercel settlements paid to date
- 34900000
Price after filing
Close on the filing date to close N calendar days later (from $0.86). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.